# Ferroptosis Findings *** **Ferroptosis-Dependence: INDIRECT / MECHANISTICALLY CONVERGENT** Direct induction of ferroptosis by AKBA has not yet been confirmed in a dedicated published study. However, AKBA's established mechanisms create conditions that are biologically convergent with ferroptosis vulnerability in cancer cells — and this convergence is meaningful enough to warrant a brief discussion here, particularly for group members whose cancers have developed resistance to apoptosis-inducing agents. *** **What ferroptosis is and why it matters in resistant cancer** Ferroptosis is a form of iron-dependent regulated cell death driven by the accumulation of lipid peroxides. It is distinct from apoptosis, necrosis, and autophagy — and, critically, cancer cells that have developed resistance to apoptosis (common in recurrent, heavily treated, or chemotherapy-resistant tumours) frequently retain sensitivity to ferroptosis. This makes the induction of ferroptosis a meaningful complementary strategy in treatment-resistant contexts. *** **Where AKBA converges with ferroptosis biology** AKBA does not directly inhibit GPX4 (the glutathione peroxidase enzyme whose inhibition is the classical trigger for ferroptosis), but its mechanisms dismantle several of the systems cancer cells rely on to *prevent* ferroptosis: 1. **PI3K/Akt suppression reduces GSH synthesis capacity** — AKBA's blockade of the Akt pathway reduces transcriptional support for glutamate-cysteine ligase (GCL), the rate-limiting enzyme in glutathione (GSH) synthesis. Since GPX4 requires GSH as a cofactor to neutralise lipid peroxides, reducing GSH availability functionally weakens the cell's ferroptosis resistance — the same vulnerability that classical ferroptosis inducers exploit 2. **FOXO1 activation drives mitochondrial ROS accumulation** — When AKBA suppresses Akt, FOXO1 is released and drives mitochondrial hydrogen peroxide generation that the depleted GSH/GPX4 system is less able to neutralise, increasing lipid peroxidation pressure. 3. **NF-κB suppression removes transcriptional support for ferroptosis-resistance genes —** NF-κB drives expression of several genes involved in lipid peroxide management and GSH homeostasis; AKBA's potent NF-κB inhibition simultaneously withdraws this suppor**t**. 4. **In glioblastoma cell death studies**, features observed in AKBA-treated glioblastoma cells were not fully consistent with classical apoptosis alone, suggesting mixed cell death mechanisms that may include ferroptotic components. This warrants formal investigation. *** **Combination rationale: AKBA + curcumin** Curcumin is a **confirmed ferroptosis inducer** — it directly depletes GSH via System Xc- inhibition and inhibits GPX4 activity. AKBA's convergent mechanisms (suppression of GSH synthesis, increased lipid peroxidation via ROS accumulation) are complementary to curcumin's direct induction of ferroptosis rather than duplicative. Together, they attack ferroptosis resistance from different angles — curcumin depletes the GSH pool directly; AKBA limits the cancer cell's ability to replenish it. This makes the combination biologically rational for treatment-resistant contexts where ferroptosis may be the remaining available cell death pathway. *** **References for Ferroptosis Findings** * AKBA anti-cancer effects via cell cycle arrest, apoptosis, and autophagy suppression in NSCLC (PI3K/Akt/FOXO1 mechanism) — PMC 2020 — * Boswellic acid activity against glioblastoma stem-like cells — PMC 2016 — * Targeted inhibition of Nrf2 reduces breast cancer chemoresistance (ferroptosis resistance context) — Bovilla et al., 2021 — * Glutathione depletion down-regulates NF-κB transactivation — Lou et al., 2007 — *** ### Jump to another Boswellia page **Core pages** * [Boswellia in Oncology Overview](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-in-oncology-overview.md) * [Evidence Summary](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/evidence-summary.md) * [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/anticancer-mechanisms.md) * [Boswellia Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type.md) **Mechanism deep dives** * [Redox Dual Action](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/redox-dual-action.md) * [NRF2 Impact](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/nrf2-impact.md) * [Ferroptosis Findings](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/ferroptosis-findings.md) * [Immune Effects](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/immune-effects.md) **Practical pages** * [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/pharmacokinetics-and-metabolism.md) * [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/safety-and-interactions.md) * [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/synergistic-combinations.md) * [Hydroxychloroquine + Boswellia](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/hydroxychloroquine-+-boswellia.md) * [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/dosing-and-timing.md) * [Sourcing Quality Boswellia](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/sourcing-quality-boswellia.md) **Cancer-type pages** * [Glioblastoma & Brain Tumours](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/glioblastoma-and-brain-tumours.md) * [Breast Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/breast-cancer.md) * [Colorectal Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/colorectal-cancer.md) * [Pancreatic Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/pancreatic-cancer.md) * [Prostate Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/prostate-cancer.md) * [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/non-small-cell-lung-cancer.md) * [Ovarian Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/ovarian-cancer.md) * [Other Cancer Types](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/other-cancer-types.md) {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/ferroptosis-findings.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.